Comment
doi: 10.1097/01.JAA.0000558364.85986.ad.
Does rivaroxaban have a role in treating patients with PAD?
Affiliations
- PMID: 31241606
- DOI: 10.1097/01.JAA.0000558364.85986.ad
Item in Clipboard
Comment
Does rivaroxaban have a role in treating patients with PAD?
JAAPA.
2019 Jul.
Abstract
Peripheral arterial disease can cause devastating health outcomes, and few therapies are available to treat this condition. Results of a secondary analysis of the COMPASS trial suggest benefit with the use of rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily. This treatment regimen could change the standard pharmacotherapeutic management practice for many patients with peripheral arterial disease.
Comment on
-
Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial.J Am Coll Cardiol. 2018 May 22;71(20):2306-2315. doi: 10.1016/j.jacc.2018.03.008. Epub 2018 Mar 11. J Am Coll Cardiol. 2018. PMID: 29540326 Clinical Trial.
Similar articles
-
Rivaroxaban versus Clopidogrel for Peripheral Artery Disease: A Clinico-Economic Approach of the COMPASS Trial.Curr Pharm Des. 2018;24(38):4516-4517. doi: 10.2174/1381612825666190101100832. Curr Pharm Des. 2018. PMID: 30621559 Review.
-
Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial.J Am Coll Cardiol. 2018 May 22;71(20):2306-2315. doi: 10.1016/j.jacc.2018.03.008. Epub 2018 Mar 11. J Am Coll Cardiol. 2018. PMID: 29540326 Clinical Trial.
-
Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both.Am Heart J. 2020 Apr;222:166-173. doi: 10.1016/j.ahj.2020.01.015. Epub 2020 Jan 28. Am Heart J. 2020. PMID: 32092505 Clinical Trial.
-
Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial.J Am Coll Cardiol. 2019 May 14;73(18):2243-2250. doi: 10.1016/j.jacc.2019.02.048. J Am Coll Cardiol. 2019. PMID: 31072566 Clinical Trial.
-
COMPASS for Vascular Surgeons: Practical Considerations.Curr Opin Cardiol. 2019 Mar;34(2):178-184. doi: 10.1097/HCO.0000000000000597. Curr Opin Cardiol. 2019. PMID: 30543542 Review.
Cited by
-
Reducing residual thrombotic risk in patients with peripheral artery disease: impact of the COMPASS trial.Drugs Context. 2020 Jul 6;9:2020-5-5. doi: 10.7573/dic.2020-5-5. eCollection 2020. Drugs Context. 2020. PMID: 32699549 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
